Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate
- PMID: 2167522
- DOI: 10.1016/0035-9203(90)90263-e
Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate
Abstract
The treatment of leishmaniasis, as currently conducted in Kenya with sodium stibogluconate, is unsatisfactory as it is expensive, resistance and relapses may occur, and major adverse effects have been reported. Recently, aminosidine (paromomycin) sulphate has shown good antileishmanial activity on its own as well as synergism with pentavalent antimony, administered concurrently. The present study was designed to assess the effectiveness of parenteral aminosidine, alone or combined with sodium stibogluconate, in visceral leishmaniasis, compared to treatment by stibogluconate alone. 53 patients were allocated to the 3 therapeutic regimes. The presenting signs and symptoms of leishmaniasis were those commonly seen in the visceral form of the disease, particularly in Kenya. At termination, clinical cures were achieved in all 53 patients with no difference between treatment groups. Spleen aspirates revealed the best parasitological results in patients receiving the combined treatment, with only 13% failures (partial cures + relapses), as opposed to 21% failures with aminosidine alone and 45% with stibogluconate alone. Treatment with aminosidine alone was the cheapest and safest regime.
Similar articles
-
Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.BMJ. 1998 Apr 18;316(7139):1200-5. doi: 10.1136/bmj.316.7139.1200. BMJ. 1998. PMID: 9583927 Free PMC article. Clinical Trial.
-
Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.J Infect Dis. 1993 Sep;168(3):715-20. doi: 10.1093/infdis/168.3.715. J Infect Dis. 1993. PMID: 8394861 Clinical Trial.
-
A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.Trans R Soc Trop Med Hyg. 2000 Jul-Aug;94(4):429-31. doi: 10.1016/s0035-9203(00)90130-5. Trans R Soc Trop Med Hyg. 2000. PMID: 11127250 Clinical Trial.
-
Drug combinations for visceral leishmaniasis.Curr Opin Infect Dis. 2010 Dec;23(6):595-602. doi: 10.1097/QCO.0b013e32833fca9d. Curr Opin Infect Dis. 2010. PMID: 20871400 Review.
-
[Treatment of visceral leishmaniasis in children].Med Trop (Mars). 2007 Feb;67(1):73-8. Med Trop (Mars). 2007. PMID: 17506279 Review. French.
Cited by
-
Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.PLoS Negl Trop Dis. 2021 Aug 31;15(8):e0009713. doi: 10.1371/journal.pntd.0009713. eCollection 2021 Aug. PLoS Negl Trop Dis. 2021. PMID: 34464401 Free PMC article.
-
Amine-Linked Flavonoids as Agents Against Cutaneous Leishmaniasis.Antimicrob Agents Chemother. 2023 May 1;65(5):e02165-20. doi: 10.1128/AAC.02165-20. Epub 2021 Mar 8. Antimicrob Agents Chemother. 2023. PMID: 33685890 Free PMC article.
-
Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.Expert Opin Drug Metab Toxicol. 2019 Jul;15(7):595-612. doi: 10.1080/17425255.2019.1629417. Epub 2019 Jun 17. Expert Opin Drug Metab Toxicol. 2019. PMID: 31174439 Free PMC article. Review.
-
Visceral leishmaniasis and HIV coinfection: current perspectives.HIV AIDS (Auckl). 2018 Oct 15;10:193-201. doi: 10.2147/HIV.S143929. eCollection 2018. HIV AIDS (Auckl). 2018. PMID: 30410407 Free PMC article. Review.
-
Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.Antimicrob Agents Chemother. 2017 Feb 23;61(3):e01169-16. doi: 10.1128/AAC.01169-16. Print 2017 Mar. Antimicrob Agents Chemother. 2017. PMID: 28031196 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources